Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 118

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 118
---
 product candidates.
To date, we have generated no revenue from our products, and we expect to incur significant expenses to complete our clinical programs
for our product candidates in the United States and elsewhere. We may never be able to obtain regulatory approval or certification for
the marketing of our product candidates in the United States or internationally. Even if we are able to commercialize some of our products
or product candidates, there can be no assurance that we will generate significant revenues or ever achieve profitability. We expect to
continue to incur significant sales and marketing, research and development, regulatory and other expenses as we begin our marketing efforts
for our products, identify customers, obtain regulatory approvals or certifications for our product candidates, conduct clinical studies
on our existing and planned product candidates and develop new product candidates or add new features to our existing products. In addition,
we expect our selling, general and administrative expenses to increase following the Business Combination due to the additional costs
associated with being a public company. The net losses that we incur may fluctuate significantly from period to period. As a result of
these increased expenditures, we will need to generate significant revenue in order to offset our operating expenses and achieve and sustain
profitability. Accordingly, we may not achieve or maintain profitability, and we may continue to incur significant losses in the future.
Even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. If we do not achieve
or sustain profitability, it will be more difficult for us to finance our business and accomplish our strategic objectives, either of
which would have a material adverse effect on our business, financial condition, results of operations and prospects and may cause the
market price of our common stock to decline.

Longevity currently has
no operating history and is acquiring certain technologies and businesses in connection with the Business Combination, and therefore we
currently have no sources of revenue. We may never become profitable.

Longevity was
formed in 2021 to pursue possible acquisitions in the medical technology and life sciences industries. Each of the Targets has had only
limited operations to date. Longevity’s and the Targets’ limited operating history makes it difficult to evaluate our current
business and predict our future results, prospects or viability. To date, we have not generated any revenue. Our ability to generate substantial
revenue and ultimately become profitable depends primarily upon our ability, alone or with our partners, to successfully obtain regulatory
approval and certification for and successfully commercialize our product candidates. Our ability to generate future revenue from